Tissue BRAF positivity was not predictive for patients' disease‐free interval (DFI; median not reached in both groups, p = 0.696), overall survival (OS; median not reached in both groups, p = 0.498), or probability of melanoma recurrence (34.6% vs. 38.5%, resp., p = 0.773), in comparison with tissue BRAF‐wild type (BRAF‐WT) melanoma. This evidence concerns the gene BRAF and melanoma.